/RCEL
RCEL Stock - AVITA Medical, Inc.
Healthcare|Medical - DevicesNASDAQ
$3.46+2.98%
+$0.10 (+2.98%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).81
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.6%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RCEL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.43 – $3.49
TARGET (TP)$4.00
STOP LOSS$3.18
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.66
52W High$14.16
52W Low$3.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $64.25M | $50.14M | $34.42M | $33.02M | $29.23M |
| Gross Profit | $55.16M | $42.36M | $28.38M | $26.92M | $23.28M |
| Gross Margin | 85.8% | 84.5% | 82.4% | 81.5% | 79.6% |
| Operating Income | $-56,593,000 | $-42,655,000 | $-27,505,000 | $-25,118,000 | $-26,540,000 |
| Net Income | $-61,845,000 | $-35,381,000 | $-26,665,000 | $-25,142,000 | $-26,583,000 |
| Net Margin | -96.3% | -70.6% | -77.5% | -76.1% | -90.9% |
| EPS | $-2.39 | $-1.40 | $-1.57 | $-1.03 | $-2.07 |
Company Overview
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
25%
Hold / Neutral
2
50%
Sell / Underperform
1
25%
Analyst Consensus🔴 Bearish
1 Bullish3 Neutral/Bearish
Price Targets
$17
Average Target
↑ 391.3% Upside
Now
$3
Low
$17
Average
$25
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 20th 2025 | BTIG Research | Upgrade | Neutral | - |
| August 8th 2025 | BTIG Research | Downgrade | Sell | $3 |
| December 24th 2024 | D. Boral Capital | Initiation | Buy | $25 |
| April 11th 2024 | BTIG Research | Downgrade | Neutral | - |
| June 27th 2023 | Cantor Fitzgerald | Initiation | Overweight | $23 |
Earnings History & Surprises
RCELBeat Rate
44%
Last 18 quarters
Avg Surprise
-11.7%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.46
Q4 2025
EPS Surprise History
Q1 24
+17.6%
$-0.28vs$-0.34
Q2 24
-180.8%
$-0.73vs$-0.26
Q3 24
-1.7%
$-0.60vs$-0.59
Q4 24
-47.6%
$-0.62vs$-0.42
Q1 25
-46.7%
$-0.44vs$-0.30
Q2 25
-35.9%
$-0.53vs$-0.39
Q3 25
-46.2%
$-0.38vs$-0.26
Q4 25
-7.0%
$-0.46vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-0.36 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.26 | $-0.38 | -46.2% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.39 | $-0.53 | -35.9% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-0.30 | $-0.44 | -46.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.42 | $-0.62 | -47.6% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.59 | $-0.60 | -1.7% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.26 | $-0.73 | -180.8% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.53 | $-0.34 | +35.8% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.34 | $-0.41 | -20.6% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.22 | $-0.37 | -68.2% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.32 | $-0.21 | +34.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.32 | $-0.22 | +31.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.35 | $-0.25 | +28.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.36 | $-0.38 | -5.6% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.43 | $-0.34 | +20.9% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.40 | $-0.24 | +40.0% | ✓ BEAT |
Q3 2021 | Aug 26, 2021 | $-0.32 | $-0.19 | +40.6% | ✓ BEAT |
Latest News
BTIG Upgrades AVITA Medical to Neutral
➖ NeutralBenzinga•Nov 20, 2025, 12:14 PM
AVITA Medical Lowers FY2025 Sales Guidance from $76.000M-$81.000M to $70.000M-$74.000M vs $75.564M Est
📉 NegativeBenzinga•Nov 6, 2025, 09:09 PM
AVITA Medical Q3 EPS $(0.46) Misses $(0.28) Estimate, Sales $16.897M Miss $18.183M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:09 PM
Lake Street Downgrades AVITA Medical to Hold, Lowers Price Target to $4
📉 NegativeBenzinga•Oct 17, 2025, 03:07 PM
Avita Medical shares are trading lower after the company appointed Cary Vance as Interim CEO. The company reported preliminary Q3 financial results.
📉 NegativeBenzinga•Oct 17, 2025, 02:24 PM
D. Boral Capital Maintains Buy on AVITA Medical, Maintains $14 Price Target
📈 PositiveBenzinga•Oct 17, 2025, 11:42 AM
Reported Earlier, AVITA Medical Announces Leadership Transition With Cary Vance As Interim CEO And Preliminary Q3 Revenue Of $17M
➖ NeutralBenzinga•Oct 17, 2025, 06:02 AM
AVITA Medical's RECELL Eligible For Up To $4,875 In CMS Reimbursement For Acute Trauma And Surgical Wounds
📈 PositiveBenzinga•Oct 1, 2025, 12:35 PM
Avita Medical stock jumps 10% after securing CE Mark for RECELL GO
📈 PositiveSeeking Alpha•Sep 15, 2025, 09:30 AM
AVITA Medical Receives CE Mark For RECELL GO, Allowing The Co To Commercialize In Europe And In Other Markets That Recognize The CE Mark
📈 PositiveBenzinga•Sep 14, 2025, 11:40 PM
D. Boral Capital Maintains Buy on AVITA Medical, Lowers Price Target to $14
➖ NeutralBenzinga•Sep 5, 2025, 11:17 AM
AVITA Medical Reaffirms RECELL System Reduces Burn Patient LOS By 36%; More Discharged Home Vs. STSG
📈 PositiveBenzinga•Sep 4, 2025, 11:51 AM
Frequently Asked Questions about RCEL
What is RCEL's current stock price?
AVITA Medical, Inc. (RCEL) is currently trading at $3.46 per share. The stock has moved +2.98% today.
What is the analyst price target for RCEL?
The average analyst price target for RCEL is $4.00, based on 1 analyst.
What sector is AVITA Medical, Inc. in?
AVITA Medical, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is RCEL's market cap?
AVITA Medical, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does RCEL pay dividends?
No, AVITA Medical, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPYX
Apyx Medical Corporation
$3.49
Mkt Cap: $0.1B
FONR
FONAR Corporation
$14.94
Mkt Cap: $0.1B
HYPR
Hyperfine, Inc.
$1.10
Mkt Cap: $0.1B
LUCD
Lucid Diagnostics Inc.
$1.12
Mkt Cap: $0.1B
NSPR
InspireMD, Inc.
$1.99
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
QIPT
Quipt Home Medical Corp.
$3.52
Mkt Cap: $0.2B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
VANI
Vivani Medical, Inc.
$1.39
Mkt Cap: $0.1B
XTNT
Xtant Medical Holdings, Inc.
$0.77
Mkt Cap: $0.1B
Explore stocks similar to RCEL for comparison